Melanoma News and Research

Latest Melanoma News and Research

Immunocore reports clinical trial data from IMCgp100 Phase I/IIa study at AACR 2015

Immunocore Limited, a world-leading biotechnology company developing novel biological drugs to treat cancer, viral infections and autoimmune diseases, today announced clinical trial data from the Phase I/IIa study of its lead programme IMCgp100, at the American Association for Cancer Research Annual Meeting 2015, in Philadelphia, USA.

20 Apr 2015

Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

Can-Fite BioPharma Ltd., a biotechnology company with a pipeline of proprietary small molecule drugs that are being developed to treat inflammatory diseases, cancer and sexual dysfunction, announced today it has submitted an application to the European Medicines Agency for Orphan Drug Designation for its drug candidate CF102 in the treatment of hepatocellular carcinoma (HCC), the most common form of liver cancer.

20 Apr 2015

New drug combination shows promise in patients with metastatic melanoma

Once again, researchers at Penn's Abramson Cancer Center have extended the reach of the immune system in the fight against metastatic melanoma, this time by combining the checkpoint inhibitor tremelimumab with an anti-CD40 monoclonal antibody drug.

20 Apr 2015

Pembrolizumab drug halts tumor growth in 76% of patients with pleural mesothelioma

The PD-1 inhibitor pembrolizumab, a cancer immunotherapy drug, shrank or halted growth of tumors in 76 percent of patients with pleural mesothelioma, a rare and deadly form of cancer that arises in the outer lining of the lungs and internal chest wall, according to a new study from researchers in the Perelman School of Medicine at the University of Pennsylvania.

20 Apr 2015

Some lung cancer patients can benefit from melanoma drugs

A subset of lung cancer patients can derive important clinical benefits from drugs that are more commonly used to treat melanoma, the authors of a new academic clinical trial in Europe have reported at the European Lung Cancer Conference (ELCC) in Geneva, Switzerland.

20 Apr 2015

James Allison to be honored with 2015 Pezcoller Foundation-AACR International Award for Cancer Research

The 2015 Pezcoller Foundation-American Association for Cancer Research (AACR) International Award for Cancer Research will be presented to James P. Allison, PhD, at the AACR Annual Meeting 2015, to be held in Philadelphia, April 18-22.

17 Apr 2015

Yale University launches clinical study to evaluate personalized medicine for metastatic melanoma

Yale University has launched a multicenter clinical trial, sponsored by Stand Up to Cancer and Melanoma Research Alliance, that will apply the latest in personalized medicine technology to treat metastatic melanoma. The trial, for which Yale is a lead site, will enroll patients lacking a particular genetic mutation for whom immune therapy did not work or was not an option.

16 Apr 2015

New research links megalin protein with malignant melanomas

Today it is not possible to predict spreading from malignant melanomas. Melanoma metastases are furthermore extremely difficult to eliminate as traditional treatment such as chemotherapy and radiotherapy is mostly ineffective. Only ten per cent of the patients survive once they reach an advanced stage with distant metastases.

16 Apr 2015

Subpopulation of tumor cells make melanoma aggressive

KU Leuven researchers have zeroed in on what makes cancer cells in melanoma so aggressive. They also succeeded in taming the effect in cell cultures.

10 Apr 2015

People with high-risk tumors containing BRAF or NRAS gene mutations have lower survival rates

Researchers from the UNC Lineberger Comprehensive Cancer Center analyzed hundreds of melanoma samples to find out if two genetic mutations more commonly found in melanoma tumors were associated with lower survival rates in patients.

9 Apr 2015

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Pharmacyclics, Inc. today announced longer-term data from a Phase II investigator-initiated study showing Waldenstrom's macroglobulinemia (WM) patients treated with IMBRUVICA (ibrutinib) experienced sustained disease control with an overall response rate (ORR) of 91% after a median of 19.1 months of treatment and a 2-year overall survival (OS) rate of 95%.

9 Apr 2015

Pediatric melanoma incidence rates decrease from 2004-2010

Melanoma is an aggressive form of skin cancer that has been increasing in incidence in adults over the past 40 years. Although pediatric melanoma is rare (5-6 children per million), most studies indicate that incidence has been increasing. In a new study scheduled for publication in The Journal of Pediatrics, researchers found that the incidence of pediatric melanoma in the United States actually has decreased from 2004-2010.

9 Apr 2015

UQDI reveals that Anisina drug can kill melanoma cells

US-Australian drug discovery company, Novogen, today announced that studies conducted at The University of Queensland Diamantina Institute revealed that experimental drug, Anisina, killed melanoma cells irrespective of their mutational status.

9 Apr 2015

Oral, Head & Neck Cancer Awareness Week: Mount Sinai experts to share tips on cancer prevention

Mouth and throat cancers are the fastest rising cancers today. They account for over 40,000 cases per year in the U.S. The American Cancer Society estimates that there will be 121,790 new cases of head and neck cancer diagnosed in 2015 and 14,240 deaths. These numbers include tongue cancer, throat cancers caused by the human papillomavirus or HPV, voice box cancer, melanoma of the face and thyroid cancers.

8 Apr 2015

St. Luke’s Cancer Center offers new Phase II oncolytic viral therapy clinical trial for advanced melanoma

St. Luke’s Cancer Center is a leader in offering clinical trials for patients with melanoma, the most unusual type of skin cancer and also the most deadly. Physicians such as Sanjiv Agarwala, MD, Chief of Medical Oncology and Hematology for St. Luke’s University Health Network and an internationally recognized melanoma specialist, are committed to bringing the most promising studies to the Lehigh Valley.

8 Apr 2015

Delcath expands global Phase 2 program to treat hepatocellular carcinoma

Delcath Systems, Inc. announces the expansion of its global Phase 2 program for the treatment of patients with unresectable hepatocellular carcinoma (HCC) or primary liver cancer.

7 Apr 2015

CXCR3 molecule is key mediator of melanoma metastasis, shows research

In a unique partnership demonstrating excellence in "team science," Dartmouth investigators from Norris Cotton Cancer Center identified a role for the molecule CXCR3 (widely known to regulate the migration of immune cells) as a key mediator of melanoma metastasis.

7 Apr 2015

Personalized cancer vaccines can be used to marshal powerful immune response

Personalized melanoma vaccines can be used to marshal a powerful immune response against unique mutations in patients' tumors, according to early data in a first-in-people clinical trial at Washington University School of Medicine in St. Louis.

6 Apr 2015

Pyrexar Medical procures hyperthermia assets of BSD Medical, begins operations

Pyrexar Medical begins operations today after completing the acquisition of hyperthermia assets held by Perseon, formerly BSD Medical. This acquisition includes substantially all hyperthermia assets, products, services and related intellectual property.

3 Apr 2015

Future Science Group to provide free access to its peer-reviewed, cancer-focused journals

Future Science Group today announced that it will provide free access to three of its peer-reviewed, cancer-focused journals for the remainder of 2015.

3 Apr 2015

Melanoma News and Research

Latest Melanoma News and Research

Immunocore reports clinical trial data from IMCgp100 Phase I/IIa study at AACR 2015

Can-Fite seeks EMA Orphan Drug Designation for CF102 in HCC

New drug combination shows promise in patients with metastatic melanoma

Pembrolizumab drug halts tumor growth in 76% of patients with pleural mesothelioma

Some lung cancer patients can benefit from melanoma drugs

James Allison to be honored with 2015 Pezcoller Foundation-AACR International Award for Cancer Research

Yale University launches clinical study to evaluate personalized medicine for metastatic melanoma

New research links megalin protein with malignant melanomas

Subpopulation of tumor cells make melanoma aggressive

People with high-risk tumors containing BRAF or NRAS gene mutations have lower survival rates

Pharmacyclics announces positive results from IMBRUVICA Phase II study in WM patients

Pediatric melanoma incidence rates decrease from 2004-2010

UQDI reveals that Anisina drug can kill melanoma cells

Oral, Head & Neck Cancer Awareness Week: Mount Sinai experts to share tips on cancer prevention

St. Luke’s Cancer Center offers new Phase II oncolytic viral therapy clinical trial for advanced melanoma

Delcath expands global Phase 2 program to treat hepatocellular carcinoma

CXCR3 molecule is key mediator of melanoma metastasis, shows research

Personalized cancer vaccines can be used to marshal powerful immune response

Pyrexar Medical procures hyperthermia assets of BSD Medical, begins operations

Future Science Group to provide free access to its peer-reviewed, cancer-focused journals

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Melanoma News and Research

Latest Melanoma News and Research

Synthetic Psychedelics: A Growing Public Health Concern

How the Vutara VXL simplifies single-molecule imaging

How cohesin mechanics and nanotracker tech are redefining DNA research

Newsletters you may be interested in